These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 29709540)

  • 1. Implications of Pharmacogenomics to the Management of IBS.
    Camilleri M
    Clin Gastroenterol Hepatol; 2019 Mar; 17(4):584-594. PubMed ID: 29709540
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacogenetics in IBS: update and impact of GWAS studies in drug targets and metabolism.
    Camilleri M; Jencks K
    Expert Opin Drug Metab Toxicol; 2024 May; 20(5):319-332. PubMed ID: 38785066
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Central Neuromodulators in Irritable Bowel Syndrome: Why, How, and When.
    Hanna-Jairala I; Drossman DA
    Am J Gastroenterol; 2024 Jul; 119(7):1272-1284. PubMed ID: 38595149
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tegaserod for the treatment of irritable bowel syndrome and chronic constipation.
    Evans BW; Clark WK; Moore DJ; Whorwell PJ
    Cochrane Database Syst Rev; 2007 Oct; (4):CD003960. PubMed ID: 17943807
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tegaserod for the treatment of irritable bowel syndrome.
    Evans BW; Clark WK; Moore DJ; Whorwell PJ
    Cochrane Database Syst Rev; 2004; (1):CD003960. PubMed ID: 14974049
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Using the Rome IV Criteria to Help Manage the Complex IBS Patient.
    Lin LD; Chang L
    Am J Gastroenterol; 2018 Apr; 113(4):453-456. PubMed ID: 29257142
    [No Abstract]   [Full Text] [Related]  

  • 7. Current and emerging drug options in the treatment of diarrhea predominant irritable bowel syndrome.
    Nee J; Zakari M; Lembo AJ
    Expert Opin Pharmacother; 2015; 16(18):2781-92. PubMed ID: 26558923
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of current drug therapies in irritable bowel syndrome: what works and does not work.
    Schoenfeld P
    Gastroenterol Clin North Am; 2005 Jun; 34(2):319-35, viii. PubMed ID: 15862938
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and tolerability of alosetron for the treatment of irritable bowel syndrome in women and men: a meta-analysis of eight randomized, placebo-controlled, 12-week trials.
    Rahimi R; Nikfar S; Abdollahi M
    Clin Ther; 2008 May; 30(5):884-901. PubMed ID: 18555935
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of harm in the pharmacotherapy of irritable bowel syndrome.
    Shah E; Kim S; Chong K; Lembo A; Pimentel M
    Am J Med; 2012 Apr; 125(4):381-93. PubMed ID: 22444104
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An Open-Label Pilot Study of Duloxetine in Patients With Irritable Bowel Syndrome and Comorbid Major Depressive Disorder.
    Lewis-Fernández R; Lam P; Lucak S; Galfalvy H; Jackson E; Fried J; Rosario M; de la Cruz AA; Sánchez-Lacay A; Díaz S; Schneier F
    J Clin Psychopharmacol; 2016 Dec; 36(6):710-715. PubMed ID: 27755218
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Diagnostic and therapeutic strategies in the irritable bowel syndrome.
    Cremonini F; Talley NJ
    Minerva Med; 2004 Oct; 95(5):427-41. PubMed ID: 15467518
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of irritable bowel syndrome.
    Trinkley KE; Nahata MC
    J Clin Pharm Ther; 2011 Jun; 36(3):275-82. PubMed ID: 21545610
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacogenetics in irritable bowel syndrome.
    Acosta A; Camilleri M
    Expert Opin Drug Metab Toxicol; 2015; 11(8):1187-91. PubMed ID: 26122800
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacogenomics in Critical Care.
    Cheek D; Howington L
    AACN Adv Crit Care; 2018; 29(1):36-42. PubMed ID: 29496712
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rationale for using serotonergic agents to treat irritable bowel syndrome.
    Baker DE
    Am J Health Syst Pharm; 2005 Apr; 62(7):700-11; quiz 712-3. PubMed ID: 15790796
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antidepressants in the treatment of irritable bowel syndrome and visceral pain syndromes.
    Crowell MD; Jones MP; Harris LA; Dineen TN; Schettler VA; Olden KW
    Curr Opin Investig Drugs; 2004 Jul; 5(7):736-42. PubMed ID: 15298070
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Systematic review: the safety and tolerability of pharmacological agents for treatment of irritable bowel syndrome--a European perspective.
    Heading R; Bardhan K; Hollerbach S; Lanas A; Fisher G
    Aliment Pharmacol Ther; 2006 Jul; 24(2):207-36. PubMed ID: 16842449
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of Comorbid Irritable Bowel Syndrome on Treatment Outcome in Non-Erosive Reflux Disease on Long-Term Proton Pump Inhibitor in Japan.
    Funaki Y; Kaneko H; Kawamura Y; Yoshimine T; Tamura Y; Izawa S; Ebi M; Ogasawara N; Sasaki M; Kasugai K
    Digestion; 2017; 96(1):39-45. PubMed ID: 28641289
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Options for patients with irritable bowel syndrome: contrasting traditional and novel serotonergic therapies.
    Johanson JF
    Neurogastroenterol Motil; 2004 Dec; 16(6):701-11. PubMed ID: 15601419
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.